Carregant...
A Novel Aminotetralin-Type Serotonin (5-HT) (2C) Receptor-Specific Agonist and 5-HT(2A) Competitive Antagonist/5-HT(2B) Inverse Agonist with Preclinical Efficacy for Psychoses
Development of 5-HT(2C) agonists for treatment of neuropsychiatric disorders, including psychoses, substance abuse, and obesity, has been fraught with difficulties, because the vast majority of reported 5-HT(2C) selective agonists also activate 5-HT(2A) and/or 5-HT(2B) receptors, potentially causing...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The American Society for Pharmacology and Experimental Therapeutics
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3989798/ https://ncbi.nlm.nih.gov/pubmed/24563531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.113.212373 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|